More and more, as momentum builds for the soon-to-be-blockbuster Winrevair, Merck’s $11.5 billion buyout of Acceleron in 2021 is looking like a savvy move. | Paving the way for the label update were ...

The FDA approved a label update for Winrevair to include that it lowers the risk for clinical worsening events in adults with ...

Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

MSD has received US Food and Drug Administration (FDA) approval for an updated indication of Winrevair (sotatercept-csrk) for ...

The FDA has expanded the approval of Winrevair to include treatment of adults with PAH WHO Group 1 to improve exercise capacity and WHO FC, and reduce the risk of clinical worsening events including ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.

The FDA has updated the label for Merck’s Winrevair (sotatercept-csrk) following results from the Phase III ZENITH trial, confirming the therapy’s ability to reduce the risk of clinical worsening ...

Merck & Co Inc (NYSE:MRK) recently received regulatory approval for Winrevair (sotatercept), a groundbreaking therapy for adults with pulmonary arterial hypertension (PAH). This approval marks a ...

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in ...